Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Ascentage Pharma Group International Unsponsored ADR ( (AAPG) ) has shared an announcement.
On December 6 and December 8, 2025, Ascentage Pharma presented significant data at the American Society of Hematology Annual Meeting regarding Lisaftoclax, a Bcl-2 inhibitor. The data from the Phase II study demonstrated Lisaftoclax’s efficacy and safety in treating relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) in patients who had failed prior treatments, including Bruton’s tyrosine kinase inhibitors. The study highlighted an objective response rate of 62.5% and a median progression-free survival of 23.89 months, showcasing Lisaftoclax as a promising treatment option for high-risk patients. These findings underscore the drug’s potential impact on Ascentage Pharma’s market positioning and its commitment to addressing unmet clinical needs in hematology.
The most recent analyst rating on (AAPG) stock is a Buy with a $48.00 price target. To see the full list of analyst forecasts on Ascentage Pharma Group International Unsponsored ADR stock, see the AAPG Stock Forecast page.
Spark’s Take on AAPG Stock
According to Spark, TipRanks’ AI Analyst, AAPG is a Underperform.
The overall stock score reflects significant financial challenges, including high debt levels and negative profitability, which are the most impactful factors. The technical analysis indicates weak momentum, and the valuation is unattractive due to negative earnings and lack of dividends. These factors collectively result in a low overall score.
To see Spark’s full report on AAPG stock, click here.
More about Ascentage Pharma Group International Unsponsored ADR
Ascentage Pharma Group International is a global, commercial-stage biopharmaceutical company focused on developing novel therapies for cancer treatment. The company specializes in discovering and commercializing differentiated therapies to address unmet medical needs, with a particular focus on cancer treatments such as Bcl-2 inhibitors.
Average Trading Volume: 7,214
Technical Sentiment Signal: Hold
Current Market Cap: $3.02B
For an in-depth examination of AAPG stock, go to TipRanks’ Overview page.